Drug intelligence / Profile preview

rVSV-UL141

Development stage: Unknown
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

rVSV-UL141 is a recombinant oncolytic virus based on vesicular stomatitis virus (VSV) engineered to express the UL141 protein from human cytomegalovirus. UL141 acts by downregulating the NK cell-activating ligand CD155, thereby inhibiting the recruitment and function of natural killer (NK) and NKT cells within tumor tissue. This modification enhances intratumoral virus replication, leading to improved tumor necrosis and prolonged survival in preclinical models of hepatocellular carcinoma (HCC). The drug is being developed as an oncolytic virotherapy for cancer, specifically for multi-focal HCC, with future applicability to other cancers suggested[1][4].

Brand names: rVSV-UL141rVSV-UL-141rVSV-UL 141
Other names: recombinant vesicular stomatitis virus expressing UL141

Targets

TNFRSF10B (DR5)

Beyond the preview

Go deeper on rVSV-UL141.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rVSV-UL141.